LiGalli

Executive Summary

LiGalli is a Dutch digital health and AI/machine learning company founded in 2021, dedicated to transforming women's health through its innovative MedRing—a personalized, programmable intravaginal drug delivery and monitoring device. The platform aims to enhance therapy compliance and generate real-world data insights for patients and healthcare professionals. As a private, early-stage company with no disclosed funding or revenue, LiGalli operates in the rapidly growing digital women's health market. The MedRing's potential to address unmet needs in contraception, hormone therapy, and reproductive health positions it as a disruptive solution, though it remains pre-commercial with no regulatory approvals or clinical trial results publicly available. The company's success hinges on executing its development and regulatory strategy, securing funding, and forging strategic partnerships. Given the competitive landscape and technical challenges, LiGalli's risk profile is elevated, but its unique value proposition offers significant upside if milestones are achieved.

Upcoming Catalysts (preview)

• Q2 2027Regulatory approval (CE mark) for MedRing35% success
• Q4 2026First-in-human clinical trial results40% success
• Q1 2027Strategic partnership or licensing deal with a women's health pharmaceutical company50% success